Get all premium features to the best stock analysis tool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, March 25, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Faheem Hasnain told investors on the Q1 2025 earnings call: "We anticipate announcing top-line results in February 2026" -- guidance that set expectations for a meaningful readout.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS) - Contact Levi & Korsinsky to Protect Your Rights

New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws. Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Company's pivotal Phase 3 trial evaluating the drug in pulmonary arterial hypertension.